dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Bordonaro, R. |
dc.contributor.author | Calvo, A. |
dc.contributor.author | Auriemma, A. |
dc.contributor.author | Hollebecque, Antoine |
dc.contributor.author | Rubovszky, G. |
dc.contributor.author | Saunders, M. P. |
dc.contributor.author | Argilés Martinez, Guillem |
dc.contributor.author | Tabernero Caturla, Josep |
dc.date.accessioned | 2022-04-22T13:36:20Z |
dc.date.available | 2022-04-22T13:36:20Z |
dc.date.issued | 2021-10 |
dc.identifier.citation | Bordonaro R, Calvo A, Auriemma A, Hollebecque A, Rubovszky G, Saunders MP, et al. Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study. ESMO Open. 2021 Oct 1;6(5):100270. |
dc.identifier.issn | 2059-7029 |
dc.identifier.uri | https://hdl.handle.net/11351/7384 |
dc.description | Càncer colorectal metastàtic; Oxaliplatina; Trifluridina/Tipiracil |
dc.description.sponsorship | The study was funded jointly by Servier, France and Taiho Pharmaceutical, Japan. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | ESMO Open;6(5) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Còlon - Càncer - Tractament |
dc.subject | Recte - Càncer - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject.mesh | Colorectal Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | /adverse effects |
dc.title | Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.esmoop.2021.100270 |
dc.subject.decs | neoplasias colorrectales |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | /efectos adversos |
dc.relation.publishversion | https://doi.org/10.1016/j.esmoop.2021.100270 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Bordonaro R] Azienda Ospedaliera ARNAS Garibaldi, Catania, Italy. [Calvo A] Gregorio Marañon University General Hospital, Madrid, Spain. [Auriemma A] Azienda Ospedaliera Universitaria Integrat, University of Verona, Verona, Italy. [Hollebecque A] Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France. [Rubovszky G] Department of Medical Oncology and Clinical Pharmacology, National Institute of Oncology Hungary, Budapest, Hungary. [Saunders MP] Christie NHS Foundation Trust, Manchester, UK. [Argilés G] Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Tabernero J] Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVic-UCC, IOB-Quiron, Barcelona, Spain |
dc.identifier.pmid | 34547581 |
dc.identifier.wos | 000704803800020 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |